A2AR antagonist 1 is primarily used in research and therapeutic applications targeting adenosine A2A receptors. These receptors play a significant role in regulating immune responses, inflammation, and neurological functions. In the field of oncology, A2AR antagonist 1 is being explored for its potential to enhance anti-tumor immunity by blocking adenosine-mediated immunosuppression in the tumor microenvironment. This could improve the efficacy of immunotherapies, such as checkpoint inhibitors. Additionally, it is investigated for its neuroprotective properties in conditions like Parkinson's disease, where adenosine A2A receptor inhibition may help alleviate motor symptoms. Its applications also extend to cardiovascular research, where it is studied for its potential to modulate blood flow and protect against ischemic injury.